Literature DB >> 18040121

Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.

Kesavan Ramasamy1, Sunil K Narayan, Shashindran Chanolean, Adithan Chandrasekaran.   

Abstract

The authors report an Indian adult female patient with a history of generalized tonic clonic seizures who developed severe features of phenytoin (DPH) toxicity on therapeutic dosage of this antiepileptic drug. Administration of 300 mg/day of DPH in this patient resulted in toxic symptoms associated with an excessive serum DPH concentration of 33 microg/ml. The PCR-RFLP analysis revealed a homozygosity involving CYP2C9*3*3. This mutation results in a marked decrease in the enzymatic activity (CYP2C9) and leads to a decreased clearance of the drug which can lead to severe acute and chronic toxicity. On switching the antiepileptic therapy from DPH to sodium valproate, there was reversal of both.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040121     DOI: 10.4103/0028-3886.33300

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  9 in total

1.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

Review 2.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2011-02-11

3.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

4.  Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-28       Impact factor: 2.441

Review 5.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2010-11-04

Review 6.  Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Authors:  Junji Saruwatari; Takateru Ishitsu; Kazuko Nakagawa
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-20

7.  CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations.

Authors:  Sheikh Nizamuddin; Shivendra Dubey; Sakshi Singh; Saurav Sharma; Pratheusa Machha; Kumarasamy Thangaraj
Journal:  Pharmgenomics Pers Med       Date:  2021-01-27

Review 8.  Pharmacogenetics in Primary Headache Disorders.

Authors:  Irina I Belyaeva; Anna G Subbotina; Ivan I Eremenko; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

9.  Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: A case report.

Authors:  S P K Kennedy Babu; V Ramesh; Agila Samidorai; N S C Charles
Journal:  J Pharm Bioallied Sci       Date:  2013-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.